S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Apollo Endosurgery (APEN) Stock Forecast, Price & News

+0.20 (+4.47%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
57,475 shs
Average Volume
177,180 shs
Market Capitalization
$187.97 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive APEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

Apollo Endosurgery logo

About Apollo Endosurgery

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$62.99 million
Book Value
$1.37 per share


Net Income
$-24.68 million
Pretax Margin




Free Float
Market Cap
$187.97 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.73 out of 5 stars

Medical Sector

48th out of 1,424 stocks

Surgical & Medical Instruments Industry

6th out of 137 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

Is Apollo Endosurgery a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apollo Endosurgery stock.
View analyst ratings for Apollo Endosurgery
or view top-rated stocks.

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Apollo Endosurgery

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) issued its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.21) EPS for the quarter, hitting analysts' consensus estimates of ($0.21). The biotechnology company earned $16.66 million during the quarter, compared to analyst estimates of $15.69 million. Apollo Endosurgery had a negative net margin of 43.31% and a negative trailing twelve-month return on equity of 95.87%. During the same period in the prior year, the firm earned ($0.17) EPS.
View Apollo Endosurgery's earnings history

What guidance has Apollo Endosurgery issued on next quarter's earnings?

Apollo Endosurgery issued an update on its FY 2022 earnings guidance on Tuesday, March, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $73 million-$75 million, compared to the consensus revenue estimate of $73.52 million.

What price target have analysts set for APEN?

5 analysts have issued 1 year target prices for Apollo Endosurgery's shares. Their forecasts range from $10.00 to $15.00. On average, they expect Apollo Endosurgery's share price to reach $12.80 in the next year. This suggests a possible upside of 174.1% from the stock's current price.
View analysts' price targets for Apollo Endosurgery
or view top-rated stocks among Wall Street analysts.

Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the following people:
  • Mr. Charles S. McKhann, CEO, Pres & Director (Age 53, Pay $963.53k)
  • Mr. Jeffrey G. Black, CFO, Sec. & Treasurer (Age 53, Pay $524.02k) (LinkedIn Profile)
  • Mr. John J. Molesphini, Exec. VP of Operations (Age 64, Pay $502.58k)
  • Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
  • Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
  • Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
  • Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
  • Dr. Christopher J. Gostout M.D., Co-Founder & Chief Medical Officer (Age 71)
  • Mr. Sydney Chung M.D., Co-Founder and Innovation Partner
  • Dr. Pankaj Jay Pasricha FACP, M.D., MBBS, Co-Founder
What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by a number of institutional and retail investors. Top institutional shareholders include CPMG Inc (9.70%), Nantahala Capital Management LLC (9.25%), Gagnon Securities LLC (3.80%), Vanguard Group Inc. (3.35%), Citigroup Inc. (2.85%) and Silverarc Capital Management LLC (2.50%). Company insiders that own Apollo Endosurgery stock include Chas Mckhann, Cpmg Inc, David Pacitti, Jeffrey G Black, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends for Apollo Endosurgery

Which major investors are selling Apollo Endosurgery stock?

APEN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Renaissance Technologies LLC, Parkman Healthcare Partners LLC, Nantahala Capital Management LLC, Russell Investments Group Ltd., Gilder Gagnon Howe & Co. LLC, Calamos Advisors LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for Apollo Endosurgery
or view top insider-selling stocks.

Which major investors are buying Apollo Endosurgery stock?

APEN stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Invesco Ltd., Silverarc Capital Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Bank of New York Mellon Corp, State Street Corp, and CPMG Inc. Company insiders that have bought Apollo Endosurgery stock in the last two years include Cpmg Inc, Jeffrey G Black, John R Barr, Neil Gagnon, and R Kent Mcgaughy Jr.
View insider buying and selling activity for Apollo Endosurgery
or or view top insider-buying stocks.

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $4.67.

How much money does Apollo Endosurgery make?

Apollo Endosurgery has a market capitalization of $187.97 million and generates $62.99 million in revenue each year. The biotechnology company earns $-24.68 million in net income (profit) each year or ($0.820010) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

Apollo Endosurgery employs 202 workers across the globe.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is www.apolloendo.com.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 279-5100, via email at [email protected], or via fax at 858-678-0900.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.